Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 8 5 W ELECTROLYTES versus TRAVASOL 5 5 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 8 5 W ELECTROLYTES versus TRAVASOL 5 5 W O ELECTROLYTES.
AMINOSYN 8.5% W/ELECTROLYTES vs TRAVASOL 5.5% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 8.5% with Electrolytes is a crystalline amino acid solution used for parenteral nutrition. It provides essential and non-essential amino acids necessary for protein synthesis, tissue repair, and maintenance of nitrogen balance. Electrolytes are included to maintain acid-base balance and normal cellular function.
TRAVASOL 5.5% W/O ELECTROLYTES is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and nitrogen balance in patients unable to tolerate enteral nutrition. It serves as a substrate for gluconeogenesis and other metabolic processes.
Intravenous infusion: 500 mL to 1000 mL of 8.5% solution (42.5-85 g amino acids) once daily, infused at a rate not exceeding 100 mL/hour.
Intravenous infusion, 500 mL to 2000 mL per day as a component of total parenteral nutrition (TPN), providing 5.5% amino acids. Rate should be individualized based on metabolic requirements and tolerance.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for essential amino acids and 0.5-2 hours for non-essential amino acids, reflecting rapid distribution and metabolism in healthy adults. In renal or hepatic impairment, half-life may be prolonged.
Not applicable as a fixed drug; the clearance of infused amino acids follows saturable kinetics with a functional half-life of approximately 30-60 minutes for free amino acids in plasma, reflecting rapid uptake and metabolism. Clinical context: continuous infusion maintains steady-state levels.
Amino acids are primarily eliminated via metabolism (deamination, transamination) and incorporation into proteins. Unmetabolized amino acids are excreted renally (approximately 5-10% of administered dose, depending on renal function and infusion rate). Fecal and biliary excretion are negligible (<1%).
Primarily renal excretion of amino acids and metabolites; approximately 70-80% of infused amino acids are converted to urea and excreted in urine, with the remainder undergoing metabolism or incorporation into body proteins. Biliary/fecal excretion is negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution